Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 27, 2020 07:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics to Present Additional Clinical Data from the STEADFAST Study of Azeliragon at the Virtual Alzheimer's Association International Conference

HIGH POINT, N.C., July 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that the Company will present at the upcoming 2020 Alzheimer's Association International...
June 13, 2020 11:00 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Presents Two Late-Breaking Poster Sessions on Simplici-T1 Study at the American Diabetes Association’s Virtual Sessions Supporting the Potential of TTP399 as First-in-Class Oral Adjunctive Therapy for Type 1 Diabetes Patients

- Treatment with TTP399 resulted in significant improvements in HbA1c with reduction in insulin, without increasing risk of hypoglycemia or diabetic ketoacidosis (DKA) - HIGH POINT, N.C., June 13,...
May 27, 2020 07:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics to Present Full Clinical Study Results from the Positive Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes at the American Diabetes Association’s 80th Virtual Scientific Sessions

HIGH POINT, N.C., May 27, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that two late-breaking abstracts reinforcing the potential of TTP399 as an oral adjunctive...
May 22, 2020 16:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Changes its 2020 Annual Meeting of Stockholders to Virtual Format

HIGH POINT, N.C., May 22, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that it will host its 2020 Annual Meeting of Stockholders (the "Annual Meeting") as a...
May 07, 2020 16:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces 2020 First Quarter Financial Results and Update

HIGH POINT, N.C., May 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the first quarter ended March 31, 2020, and provided an update on recent...
February 20, 2020 18:57 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces 2019 Fourth Quarter and Full Year Financial Results and Provides Corporate Update

HIGH POINT, N.C., Feb. 20, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq:VTVT) today reported financial results for the fourth quarter and year ended December 31, 2019, and provided an...
February 10, 2020 07:00 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces Positive Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399, Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes

- TTP399, a novel glucokinase activator, achieves primary objective of a statistically significant reduction in HbA1c, without increases in hypoglycemia or ketoacidosis - Company to host investor...
February 07, 2020 16:05 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics to Host Investor Call and Announce Results from Part 2 of the Phase 2 Simplici-T1 Study of TTP399 – Potential First-in-Class Oral Adjunctive Therapy for Patients with Type 1 Diabetes

HIGH POINT, N.C., Feb. 07, 2020 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) today announced that it will release the topline results from Part 2 of the Phase 2 Simplici-T1 trial...
December 02, 2019 07:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics to Present at the 31st Annual Piper Jaffray Healthcare Conference

HIGH POINT, N.C., Dec. 02, 2019 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
October 30, 2019 17:30 ET | Source: vTv Therapeutics Inc.

vTv Therapeutics Announces 2019 Third Quarter Financial Results and Update

SimpliciT-1 Study of TTP399 in patients with type 1 diabetes fully-enrolled Elevage Study of azeliragon in patients with mild Alzheimer’s disease with type 2 diabetes actively enrolling HIGH POINT,...